Compound Evidence File
#EC-2026-0933
PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7
Filed under Raw Materials. The bureau holds 157 laboratory returns for this compound from 46 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
46 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 24 Feb 2026 | 12 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 10.0 | 10.0 | 5 Apr 2026 | 6 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Nov 2025 | 18 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Feb 2026 | 2 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Dec 2025 | 15 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Mar 2026 | 15 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 25 Mar 2026 | 28 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 10.0 | 10.0 | 28 Jun 2026 | 6 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 10.0 | 10.0 | 24 May 2026 | 28 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 1 May 2026 | 15 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Jun 2026 | 16 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Jun 2026 | 24 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Mar 2026 | 4 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 10.0 | 10.0 | 10.0 | 18 Mar 2026 | 19 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Nov 2025 | 10 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Jan 2026 | 7 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 6 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Jun 2026 | 1 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Nov 2025 | 19 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 9.9 | 18 Mar 2026 | 8 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 9.9 | 3 Mar 2026 | 24 Jul 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 9.7 | 9.7 | 9.7 | 24 Apr 2025 | 24 Apr 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.9 | 8.0 | 9.9 | 21 May 2026 | 21 May 2026 |
| Reta-PeptideCASE #VI-2026-0756 | X | 1 | 8.9 | 8.9 | 8.9 | 28 Mar 2025 | 28 Mar 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.8 | 8.1 | 9.6 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.7 | 7.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.6 | 7.3 | 9.5 | 21 May 2026 | 21 May 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 8.4 | 8.4 | 8.4 | 13 Jun 2025 | 13 Jun 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.2 | 8.2 | 8.2 | 11 Jun 2025 | 11 Jun 2025 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 1 | 8.2 | 8.2 | 8.2 | 7 May 2025 | 7 May 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.0 | 7.5 | 8.7 | 23 May 2026 | 23 May 2026 |
| Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 | X | 1 | 7.8 | 7.8 | 7.8 | 7 May 2025 | 7 May 2025 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Apr 2025 | 2 Apr 2025 |
| Mai PeptideCASE #VI-2026-0769 | X | 5 | 7.4 | 5.9 | 8.9 | 2 Jul 2025 | 19 Jan 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 6 | 6.9 | 5.4 | 8.4 | 13 Jun 2025 | 24 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 4 | 6.8 | 5.4 | 8.5 | 2 Apr 2025 | 24 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 13 | 6.5 | 4.0 | 9.5 | 2 Jul 2025 | 26 Jan 2026 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 6.4 | 6.4 | 6.4 | 28 Mar 2025 | 28 Mar 2025 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 2 | 5.5 | 5.5 | 5.6 | 20 Jun 2025 | 25 May 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 5.4 | 5.2 | 5.6 | 13 Feb 2025 | 17 May 2026 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 2 | 5.3 | 5.3 | 5.4 | 3 Jul 2025 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 2 | 5.0 | 5.0 | 5.0 | 2 Jul 2025 | 21 May 2026 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 3.4 | 3.4 | 3.4 | 2 Apr 2025 | 2 Apr 2025 |
| Zhuoyue BiotechnologyCASE #VI-2026-0632 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
Open any subject to view the batch-level evidence for PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 alone.